Ergotamine abuse. Do patients benefit from withdrawal?

Cephalalgia

Department of Neurology, Rigshospitalet, Copenhagen, Denmark.

Published: March 1981

A follow-up study of 40 patients (migraine 39, cluster headache 1) previously treated for ergotamine abuse was conducted. Their statements regarding ergotamine intake were checked using butalbital (contained in the suppositories abused by 90% of the patients) as a tracer, and later by contact with the family doctor. Eleven patients abused ergotamine again during a median observation time of 21 months. Nineteen patients had more than a 50% reduction in headache days after withdrawal and half of the patients were relieved of other symptoms of ergotamine toxicity. Even with a failure rate of approximately 25% it is concluded that efforts to withdraw after abuse of ergotamine are worthwhile.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1468-2982.1981.tb00005.xDOI Listing

Publication Analysis

Top Keywords

ergotamine abuse
8
ergotamine
6
patients
6
abuse patients
4
patients benefit
4
benefit withdrawal?
4
withdrawal? follow-up
4
follow-up study
4
study patients
4
patients migraine
4

Similar Publications

Dopamine (DA) D2-like receptors in both the central nervous system (CNS) and the periphery are key modulators of metabolism. Moreover, disruption of D2-like receptor signaling is implicated in dysglycemia. Yet, the respective metabolic contributions of CNS versus peripheral D2-like receptors, including D2 (D2R) and D3 (D3R) receptors, remain poorly understood.

View Article and Find Full Text PDF

Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia.

Biomedicines

August 2023

Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A, Pereira 660003, Colombia.

Research Objective: To identify the frequency of opioid use in a group of patients diagnosed with migraine in Colombia.

Methods: Study of a retrospective cohort of patients with a diagnosis of migraine and a first prescription of antimigraine drugs from emergency services and a priority outpatient clinic. Sociodemographic, clinical, and pharmacological variables were identified; a 12-month follow-up was carried out to identify the use of a new opioid.

View Article and Find Full Text PDF

Pharmacological interventions for antisocial personality disorder.

Cochrane Database Syst Rev

September 2020

Arnold Lodge, Nottinghamshire Healthcare NHS Foundation Trust, Leicester, UK.

Background: Antisocial personality disorder (AsPD) is associated with rule-breaking, criminality, substance use, unemployment, relationship difficulties, and premature death. Certain types of medication (drugs) may help people with AsPD. This review updates a previous Cochrane review, published in 2010.

View Article and Find Full Text PDF

Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System.

Neurology

April 2020

From the Departments of Neurology (J.V.R., J.H.S.) and Biostatistics (R.J.B.), Mayo Clinic, Scottsdale; Departments of Child Health and Medicine, Division of Medical Toxicology and Precision Medicine (A.M.K.), University of Arizona College of Medicine-Phoenix; and Department of Medical Toxicology and Banner Poison and Drug Information Center (A.M.K.), Banner-University Medical Center Phoenix, AZ.

Objective: To examine the clinical outcomes of intentional overdoses involving triptans and ergotamines with a retrospective review of the National Poison Data System (NPDS).

Methods: This was a 5-year retrospective cross-sectional study (2014-2018) using the NPDS. Demographics, exposure characteristics, and outcomes were described.

View Article and Find Full Text PDF

Acute coronary syndrome with elevation of ST associated with ergotamine abuse.

Rom J Intern Med

March 2019

Department of Cardiology and Physiology, Universitary Hospital, Universidad Abierta Interamericana,Faculty of Medicine, Buenos Aires, Argentine.

There are few case reports of cases of carotid and aortic dissection related to the ergotamine abuse, but the cases that affect the coronary arteries is a very rare coronary. We present a patient of a 48-year-old female with an ST-segment elevation myocardial infarction attributable to chronic ergotamine use. The coronary angiography showed dissection of right coronary artery proximal.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!